Toru Harabayashi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Toru Harabayashi has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Satoru Maruyama
Affiliation Department of Urology, National Hospital Organisation Hokkaido Cancer Center, Sapporo, Japan
3 shared publications Ataru Sazawa
Department of Urology, Obihiro Kosei Hospital, Obihiro, Hokkaido, Japan
2 shared publications- Hironobu Hata
Department of Dentistry and Oral Surgery NHO Hokkaido Cancer Center Sapporo Hokkaido Japan
2 shared publications - Ikuya Miyamoto
Oral Diagnosis and Medicine, Faculty of Dental Medicine Hokkaido University Sapporo Hokkaido Japan
2 shared publications - Nobuo Shinohara
Department of Renal and Genitourinary Surgery Hokkaido University Graduate School of Medicine Sapporo Japan
2 shared publications - Takahiro Osawa
Department of Urology and Molecular Oncology, Graduate School of Medicine and Dental Sciences, Niigata University, Niigata, Japan
2 shared publications
Latest Publications
- 10 July 2026
- Published by Wiley in Oral Science International
- Vol. 23 (3) , e70056
Medication‐Related Osteonecrosis of the Jaw Occurring During Cabozantinib Treatment for Renal Cell Carcinoma: A Report of Three Cases
Background: Medication‐related osteonecrosis of the jaw (MRONJ) is a side effect mainly caused by antiresorptive agents (ARAs), but multi‐kinase inhibitors can also rarely cause MRONJ. Here, three cases of MRONJ that occurred in a single center during the use of cabozantinib for renal cell carcinoma are described. Case Presentations: Identified local triggers during cabozantinib therapy included inflammation around a bridge pontic, apical periodontitis, and ill‐fitting dentures. During MRONJ development, > 84, 2, and 31 months had elapsed since the last administration of ARAs, respectively. Conclusion: Dental oncologists and general dentists should be aware of the potential risk of MRONJ in patients receiving cabozantinib, particularly those with prior exposure to ARAs.
- 10 July 2026
- Published by Wiley in Oral Science International
- Vol. 23 (3) , e70056
Medication‐Related Osteonecrosis of the Jaw Occurring During Cabozantinib Treatment for Renal Cell Carcinoma: A Report of Three Cases
Background: Medication‐related osteonecrosis of the jaw (MRONJ) is a side effect mainly caused by antiresorptive agents (ARAs), but multi‐kinase inhibitors can also rarely cause MRONJ. Here, three cases of MRONJ that occurred in a single center during the use of cabozantinib for renal cell carcinoma are described. Case Presentations: Identified local triggers during cabozantinib therapy included inflammation around a bridge pontic, apical periodontitis, and ill‐fitting dentures. During MRONJ development, > 84, 2, and 31 months had elapsed since the last administration of ARAs, respectively. Conclusion: Dental oncologists and general dentists should be aware of the potential risk of MRONJ in patients receiving cabozantinib, particularly those with prior exposure to ARAs.
- 14 January 2026
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 34 (2) , 94
Efficacy and risks of drug holiday in the management of medication-related osteonecrosis of the jaw in cancer patients: a single-center retrospective study
Purpose Discontinuing bone-modifying agents (BMAs) during management of medication-related osteonecrosis of the jaw (MRONJ) remains controversial. This retrospective study evaluates the impact and potential risks of BMA drug holidays in cancer patients with MRONJ. Methods We retrospectively classified 156 cancer patients with MRONJ into four groups: BMA withdrawal with conservative therapy (WC, n = 40), withdrawal with surgical therapy (WS, n = 63), non-withdrawal with conservative therapy (nWC, n = 30), and non-withdrawal with surgical therapy (nWS, n = 23). In the WS group, surgery was performed after radiographic confirmation of bone sequestration following BMA discontinuation. Healing rates and skeletal-related events (SREs) incidence were analyzed. Results The healing rates from MRONJ onset were 94.7% in the WS group, 53.6% in the nWS group, 25.5% in the WC group, and 0% in the nWC group. Among surgical patients, the healing rate from the time of surgery was significantly higher in the WS group (92.3%) than in the nWS group (47.8%) (hazard ratio = 3.23, p < 0.05). The incidence of SREs was 52.3% in the WC group, 15.8% in the WS group, 16.7% in the nWS group, and 4.2% in the nWC group. The WC group showed a significantly higher incidence of SREs compared with the WS and nWS groups. Conclusion A therapeutic strategy involving planned BMA discontinuation followed by delayed surgical intervention after radiographic confirmation of sequestrum formation, may be associated with improved healing outcomes. This approach does not appear to increase the incidence of SREs, particularly when BMA therapy is appropriately resumed after successful surgical healing.
- 14 January 2026
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 34 (2) , 94
Efficacy and risks of drug holiday in the management of medication-related osteonecrosis of the jaw in cancer patients: a single-center retrospective study
Purpose Discontinuing bone-modifying agents (BMAs) during management of medication-related osteonecrosis of the jaw (MRONJ) remains controversial. This retrospective study evaluates the impact and potential risks of BMA drug holidays in cancer patients with MRONJ. Methods We retrospectively classified 156 cancer patients with MRONJ into four groups: BMA withdrawal with conservative therapy (WC, n = 40), withdrawal with surgical therapy (WS, n = 63), non-withdrawal with conservative therapy (nWC, n = 30), and non-withdrawal with surgical therapy (nWS, n = 23). In the WS group, surgery was performed after radiographic confirmation of bone sequestration following BMA discontinuation. Healing rates and skeletal-related events (SREs) incidence were analyzed. Results The healing rates from MRONJ onset were 94.7% in the WS group, 53.6% in the nWS group, 25.5% in the WC group, and 0% in the nWC group. Among surgical patients, the healing rate from the time of surgery was significantly higher in the WS group (92.3%) than in the nWS group (47.8%) (hazard ratio = 3.23, p < 0.05). The incidence of SREs was 52.3% in the WC group, 15.8% in the WS group, 16.7% in the nWS group, and 4.2% in the nWC group. The WC group showed a significantly higher incidence of SREs compared with the WS and nWS groups. Conclusion A therapeutic strategy involving planned BMA discontinuation followed by delayed surgical intervention after radiographic confirmation of sequestrum formation, may be associated with improved healing outcomes. This approach does not appear to increase the incidence of SREs, particularly when BMA therapy is appropriately resumed after successful surgical healing.
- Open Access
- 1 January 2022
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 40 (1) , 13.e19-13.e27
Efficacy of nivolumab plus ipilimumab as first-line therapy for primary tumors in patients with renal cell carcinoma
- 1 January 2022
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 40 (1) , 13.e19-13.e27
Open AccessEfficacy of nivolumab plus ipilimumab as first-line therapy for primary tumors in patients with renal cell carcinoma
- Open Access
- 8 November 2019
- Published by Springer Nature in BMC Urology
- Vol. 19 (1) , 1-11
Cost comparison between open radical cystectomy, laparoscopic radical cystectomy, and robot-assisted radical cystectomy for patients with bladder cancer: a systematic review of segmental costs
Background: Robot-assisted radical cystectomy is becoming a common treatment for bladder carcinoma. However, in comparison with open radical cystectomy, its cost-effectiveness has not been confirmed. Although few published reviews have compared total costs between the two surgical procedures, no study has compared segmental costs and explained their impact on total costs. Methods: A systematic review was conducted based on studies on the segmental costs of open, laparoscopic, and robot-assisted radical cystectomy using PubMed, Web of Science, and Cochrane Library databases to provide insight into cost-effective management methods for radical cystectomy. The segmental costs included operating, robot-related, complication, and length of stay costs. A sensitivity analysis was conducted to determine the impact of the annual number of cases on the per-case robot-related costs. Results: We identified two studies that compared open and laparoscopic surgeries and nine that compared open and robotic surgeries. Open radical cystectomy costs were higher than those of robotic surgeries in two retrospective single-institution studies, while robot-assisted radical cystectomy costs were higher in 1 retrospective single-institution study, 1 randomized controlled trial, and 4 large database studies. Operating costs were higher for robotic surgery, and accounted for 63.1–70.5% of the total robotic surgery cost. Sensitivity analysis revealed that robot-related costs were not a large proportion of total surgery costs in institutions with a large number of cases but accounted for a large proportion of total costs in centers with a small number of cases. Conclusions: The results show that robot-assisted radical cystectomy is more expensive than open radical cystectomy. The most effective methods to decrease costs associated with robotic surgery include a decrease in operating time and an increase in the number of cases. Further research is required on the cost-effectiveness of surgeries, including quality measures such as quality of life and quality-adjusted life years.
- 8 November 2019
- Published by Springer Nature in BMC Urology
- Vol. 19 (1) , 1-11
Open AccessCost comparison between open radical cystectomy, laparoscopic radical cystectomy, and robot-assisted radical cystectomy for patients with bladder cancer: a systematic review of segmental costs
Background: Robot-assisted radical cystectomy is becoming a common treatment for bladder carcinoma. However, in comparison with open radical cystectomy, its cost-effectiveness has not been confirmed. Although few published reviews have compared total costs between the two surgical procedures, no study has compared segmental costs and explained their impact on total costs. Methods: A systematic review was conducted based on studies on the segmental costs of open, laparoscopic, and robot-assisted radical cystectomy using PubMed, Web of Science, and Cochrane Library databases to provide insight into cost-effective management methods for radical cystectomy. The segmental costs included operating, robot-related, complication, and length of stay costs. A sensitivity analysis was conducted to determine the impact of the annual number of cases on the per-case robot-related costs. Results: We identified two studies that compared open and laparoscopic surgeries and nine that compared open and robotic surgeries. Open radical cystectomy costs were higher than those of robotic surgeries in two retrospective single-institution studies, while robot-assisted radical cystectomy costs were higher in 1 retrospective single-institution study, 1 randomized controlled trial, and 4 large database studies. Operating costs were higher for robotic surgery, and accounted for 63.1–70.5% of the total robotic surgery cost. Sensitivity analysis revealed that robot-related costs were not a large proportion of total surgery costs in institutions with a large number of cases but accounted for a large proportion of total costs in centers with a small number of cases. Conclusions: The results show that robot-assisted radical cystectomy is more expensive than open radical cystectomy. The most effective methods to decrease costs associated with robotic surgery include a decrease in operating time and an increase in the number of cases. Further research is required on the cost-effectiveness of surgeries, including quality measures such as quality of life and quality-adjusted life years.
- Open Access
- 29 December 2015
- Published by Springer Nature in Surgical Endoscopy
- Vol. 30 (10) , 4640-4645
Laparoscopic resection of paraaortic/paracaval neurogenic tumors: surgical outcomes and technical tips
Due to variations in location and size, laparoscopic surgery for paraaortic or paracaval neurogenic tumors is challenging. We evaluated the surgical outcomes, as well as surgical tips and tricks.
- 29 December 2015
- Published by Springer Nature in Surgical Endoscopy
- Vol. 30 (10) , 4640-4645
Open AccessLaparoscopic resection of paraaortic/paracaval neurogenic tumors: surgical outcomes and technical tips
Due to variations in location and size, laparoscopic surgery for paraaortic or paracaval neurogenic tumors is challenging. We evaluated the surgical outcomes, as well as surgical tips and tricks.
- 1 February 2012
- Published by Elsevier in European Urology Supplements
- Vol. 11 (1) , e1052-e1052a
1052 Urethral length and diameter of the external urethral sphincter as predictors of continence after laparoscopic radical prostatectomy
- 1 February 2012
- Published by Elsevier in European Urology Supplements
- Vol. 11 (1) , e1052-e1052a
1052 Urethral length and diameter of the external urethral sphincter as predictors of continence after laparoscopic radical prostatectomy
- 1 March 2011
- Published by Elsevier in European Urology Supplements
- Vol. 10 (2) , 348
V16 OUTCOME OF REGIONAL LYMPH NODE DISSECTION IN CONJUNCTION WITH LAPAROSCOPIC NEPHROURETERECTOMY FOR UROTHELIAL CARCINOMA OF UPPER URINARY TRACT
- 1 March 2011
- Published by Elsevier in European Urology Supplements
- Vol. 10 (2) , 348
V16 OUTCOME OF REGIONAL LYMPH NODE DISSECTION IN CONJUNCTION WITH LAPAROSCOPIC NEPHROURETERECTOMY FOR UROTHELIAL CARCINOMA OF UPPER URINARY TRACT